Regent Pacific Group's (HKG:0575) commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group, has submitted a new drug application (NDA) for Senstend to China's National Medical Products Administration, a Wednesday bourse filing said.
Senstend is a proprietary formulation of two marketed drugs, lidocaine and prilocaine, developed for the treatment of premature ejaculation.
Jiangsu Wanbang Biopharmaceutical Group is a wholly-controlled company of Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196).
Price (HKD): $0.33, Change: $-0.015, Percent Change: -4.35%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。